Mid dose ANAVEX2-73

DRUG2 trials

Sponsors

Anavex Life Sciences Corp.

Conditions

Alzheimer DiseaseParkinsons Disease With Dementia

Phase 2

ANAVEX2-73 Study in Parkinson's Disease Dementia

CompletedNCT03774459

Anavex Life Sciences Corp.Parkinsons Disease With Dementia

Start: 2018-07-09End: 2020-09-30Updated: 2020-10-22

ANAVEX2-73 for Treatment of Early Alzheimer's Disease

CompletedNCT03790709

Anavex Life Sciences Corp.Alzheimer Disease

Start: 2018-07-03End: 2022-06-30Updated: 2022-07-14

Related Papers

Sigma-1 Receptor Ligand Blarcamesine (ANAVEX 2-73) for Alzheimer's Disease: A Systematic Review.

2026-08-06

Blarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial.

2025-01-0123 citations

A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimer's disease therapy: Analysis of the blarcamesine (ANAVEX2‐73) Phase 2a clinical study

Alzheimer s & Dementia Translational Research & Clinical Interventions2020-01-0178 citations